Provided by Parkinson & Movement Disorder Alliance

Nearly all people with Parkinson’s experience non-motor symptoms prior to motor manifestations, and additional non-motor features typically develop as the disease progresses. Non-motor symptoms can be among the most bothersome for patients and are critical to address. This session focuses on common non-motor symptoms, describing their timing in the disease course and pharmacological treatment.

Estimated time to complete activity: 45 minutes

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of .75 AMA PRA Category 1.0 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the pathophysiological mechanisms underlying common non-motor symptoms in Parkinson’s disease and their progression across disease stages
• Identify common non-motor symptoms of Parkinson’s disease and assess their impact on patient quality of life
• Formulate individualized treatment strategies for non-motor symptoms in Parkinson’s disease using pharmacologic and non-pharmacologic approaches

Faculty

Fernando Pagan, MD
Professor and Vice Chairman for the Department of Neurology at MedStar Georgetown University Hospital

Fernando L. Pagan, MD is a board-certified neurologist and Professor and Vice Chairman for the Department of Neurology at MedStar Georgetown University Hospital in Washington DC. He is the Director of the Movement Disorders Program and the Medical Director of MedStar Georgetown's National Parkinson Foundation Center of Excellence, as well as the Fellowship Director for the clinical research done at the Movement Disorders Fellowship at MedStar Georgetown. He also serves as the Medical Director of the Translational Neuroscience Program (TNP). He is a member of the Functional Neurosurgery Team for Movement Disorders, performing preoperative evaluations and programming for deep brain stimulators in Parkinson disease, essential tremor and dystonia. After receiving his medical degree from Georgetown University and completing an internal medicine internship and neurology residency at MedStar Georgetown, he completed a fellowship in movement disorders and magnetic resonance spectroscopy at the National Institute of Neurological Diseases and Stroke within the National Institutes of Health. His special interests include Parkinson disease, parkinsonism and other related disorders, ataxia, essential tremor, dystonia, and tics. He is an expert in botulinum toxin treatment for dystonia, tremor, spasticity, and tics.

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Fernando Pagan, MD
• Site investigator for research supported by Amneal and Kyowa Kirin
• Other grant support from Medtronic
• Speakers’ Bureau, consultant, and/or advisory board member for AbbVie, Acadia, Amneal, Acorda, Kyowa Kirin, Teva, Supernus, Merz, and Neurocrine

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Leslie Cloud, MD
• Site investigator for research supported by Amneal and Intracellular Therapies
• Speakers’ Bureau, consultant, and/or advisory board member for Amneal

• Britt Stone, MD
• Speakers’ Bureau, consultant, and/or advisory board member for Boston Scientific

• Jason Rivera, MPH
• No disclosures to report

• Clarisse Goas, NP
• Principal or site investigator for research supported by AskBio
• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America

• Anissa Mitchel, LCSW
• No disclosures to report

• Kelly Papesh, DNP
• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America

• Mary Ann Chapman, PhD
• Consultant for Allergan Aesthetics

• Fernando Pagan, MD
• Site investigator for research supported by Amneal and Kyowa Kirin
• Other grant support from Medtronic
• Speakers’ Bureau, consultant, and/or advisory board member for AbbVie, Acadia, Amneal, Acorda, Kyowa Kirin, Teva, Supernus, Merz, and Neurocrine

• Yasar Torres-Yaghi, MD
• No disclosures to report

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

This activity is supported by independent medical education grants from Merz, AbbVie, Kyowa Kirin, and Mitsubishi Tanabe Pharma America.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org